Inactive Instrument

Imago BioSciences, Inc.

IMGO

US45250K1079

Biotechnology & Medical Research

Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P Global BMI Index

January 11, 2023 at 12:00 am EST

Latest news about Imago BioSciences, Inc.

Imago BioSciences, Inc. Announces Board Changes	23-01-11	CI
Merck & Company Concludes Cash Tender Offer to Acquire Imago BioSciences	23-01-11	MT
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite Index	23-01-11	CI
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P Global BMI Index	23-01-11	CI
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P TMI Index	23-01-11	CI
Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc..	23-01-10	CI
Insider Sell: Imago Biosciences	22-12-29	MT
Insider Sell: Imago Biosciences	22-12-29	MT
Insider Sell: Imago Biosciences	22-12-20	MT
Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis	22-12-20	CI
Insider Sell: Imago Biosciences	22-12-19	MT
Insider Sell: Imago Biosciences	22-12-19	MT
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Biotechnology Index	22-12-16	CI
Imago BioSciences Reports 'Positive' Mid-Stage Results in Thrombocythemia Trial	22-12-12	MT
Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022	22-12-12	CI
Merck Begins Tender Offer to Acquire Imago BioSciences	22-12-12	MT
Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia	22-11-30	CI
North American Morning Briefing : China Reopening -2-	22-11-29	DJ
Stifel Nicolaus Downgrades Imago BioSciences to Hold From Buy, Adjusts Price Target to $36 From $35	22-11-28	MT
PUMP / DUMP #52 : This week's gainers and losers	22-11-25
Jefferies Downgrades Imago BioSciences to Hold From Buy, Adjusts Price Target to $36 From $35	22-11-22	MT
Cowen Downgrades Imago BioSciences to Market Perform From Outperform, Price Target is $36	22-11-22	MT
HC Wainwright Downgrades Imago BioSciences to Neutral From Buy, Lifts Price Target to $36 From $35	22-11-22	MT
North American Morning Briefing : Stock Gains Seen -2-	22-11-22	DJ
Merck & Co. To Buy Bone Marrow Disease-focused Imago BioSciences For $1.4 Billion	22-11-21	MT

Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It focuses on providing treatment for patients with cancer and bone marrow diseases. The Company's lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company's product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The Company also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. It tests bomedemstat in mouse models of MPNs as a single agent.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+48.83%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research